Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gan and Lee PharmaceuticalsSHSE:603087 -2.27%89 OCF Margin % is 19.38% as of Jun. 2026, which is 21% below its 10-year median of 24.60. GuruFocus rates SHSE:603087 with a GF Score™ of 89/100 and a GF Value™ of ¥73.06 (Fairly Valued). The stock has 5 warning signs investors should review. Among 813 Medical Devices & Instruments companies, Gan and Lee Pharmaceuticals ranks better than 84.75% on this metric.
The historical rank and industry rank for Gan and Lee Pharmaceuticals's OCF Margin % or its related term are showing as below:
SHSE:603087'
s OCF Margin % Range Over the Past 10 Years
Min: 4.2 Med: 24.6 Max: 40.06
Current: 23
During the past 13 years, the highest OCF Margin % of Gan and Lee Pharmaceuticals was 40.06%. The lowest was 4.20%. And the median was 24.60%.
SHSE:603087's OCF Margin % is ranked better than 84.75% of 813
companies
in the Medical Devices & Instruments industry
Industry Median: 6.65
vs SHSE:603087: 23.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603087 vs ISRG, BDX, RMD: OCF Margin % Comparison
For the Medical Instruments & Supplies subindustry, Gan and Lee Pharmaceuticals's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gan and Lee Pharmaceuticals OCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gan and Lee Pharmaceuticals's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Gan and Lee Pharmaceuticals's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gan and Lee Pharmaceuticals (SHSE:603087) has a OCF Margin % of 19.38% as of Jun. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Gan and Lee Pharmaceuticals and its competitors. This is 21% below median its historical median of 24.60. Over the past decade, Gan and Lee Pharmaceuticals' OCF Margin % has ranged from 4.20 to 40.06. According to the industry distribution chart, Gan and Lee Pharmaceuticals ranks #124 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 15.3%.
Is Gan and Lee Pharmaceuticals' OCF Margin % too high?
Gan and Lee Pharmaceuticals' current OCF Margin % of 19.38% is 21% below median its 10-year median of 24.60. Over the past 10 years, this metric has ranged from a low of 4.20 to a high of 40.06. The Medical Devices & Instruments industry median OCF Margin % is 6.65. Gan and Lee Pharmaceuticals' value of 19.38% is 191.4% above this industry median. Based on the distribution chart, Gan and Lee Pharmaceuticals ranks #124 out of 813 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Gan and Lee Pharmaceuticals has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gan and Lee Pharmaceuticals' OCF Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Gan and Lee Pharmaceuticals ranks #124 out of 813 companies for OCF Margin %. This places Gan and Lee Pharmaceuticals in the top 15% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 6.65. Gan and Lee Pharmaceuticals' value of 19.38% is 191.4% above this benchmark. Historically, Gan and Lee Pharmaceuticals' own OCF Margin % has ranged from 4.20 to 40.06 over the past decade. While the company's 10-year median is 24.60 vs. the industry median of 6.65, Gan and Lee Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Devices & Instruments company?
The median OCF Margin % among Medical Devices & Instruments companies is 6.65, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gan and Lee Pharmaceuticals's current OCF Margin % of 19.38% is 191.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Gan and Lee Pharmaceuticals and its competitors. For the Medical Devices & Instruments industry, the median OCF Margin % is 6.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gan and Lee Pharmaceuticals's current OCF Margin % is 19.38%, which is 21% below median its own 10-year median of 24.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gan and Lee Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals (SHSE:603087) is currently considered Fairly Valued. The stock's GF Value™ is ¥73.06, compared to a current price of ¥66.34 — trading 9.2% below its estimated fair value. The current OCF Margin % is 19.38%, which is 21% below median its 10-year median of 24.60 and 191.4% above the Medical Devices & Instruments industry median of 6.65. Gan and Lee Pharmaceuticals' overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Gan and Lee Pharmaceuticals (SHSE:603087), the current OCF Margin % is 19.38% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gan and Lee Pharmaceuticals (SHSE:603087) Overvalued in 2026?
Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals stock appears to be undervalued.
The current stock price of ¥66.34 is trading 9.2% below its estimated GF Value™ of ¥73.06.
GuruFocus considers Gan and Lee Pharmaceuticals to be Fairly Valued.
Key valuation signals for SHSE:603087:
OCF Margin %: 19.38% (21% below median its 10-year median of 24.60)
GF Value™: ¥73.06 vs. price of ¥66.34 (9.2% below fair value)
Industry Position: 191.4% above the Medical Devices & Instruments median (#124 of 813)
No single metric tells the full story. See the SHSE:603087 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603087 has been successfully added to your 
